Clinical trial
Heart and Estrogen-Progestin Replacement Study (HERS)
NCT00319566 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00319566 |
|---|---|
| Title | Heart and Estrogen-Progestin Replacement Study (HERS) |
| Official title | Heart and Estrogen-Progestin Replacement Study (HERS) |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Coronary Heart Disease |
| Intervention type | Drug |
| Interventions | Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily |
| Enrollment | 2,430 |
| Start date | Jul 1, 1992 |
| Completion | Jul 1, 2001 |
| First posted | Apr 27, 2006 |
| Last update posted | Apr 27, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: